The new Epoch of Antithrombotic Therapy in the Long-Term Prevention of a non-Cardioembolic Stroke

This article presents current opinions on the role of antithrombotic therapy in secondary prevention of cardiovascular diseases (CVD) in patients after noncardioembolic stroke or a transient ischemic attack on the background of sinus rhythm. This review analytically analyses evidence-based data on antithrombotic drugs used for this secondary prevention. Despite the fact that acetylsalicylic acid (ASA) is still a “gold standard” for prevention of noncardioembolic stroke, the search for rational combinations of antithrombotic drugs to increase the effectiveness of preventive treatment is relevant. The question whether the rivaroxaban treatment as monotherapy or in combination with ASA is more effective than the ASA monotherapy for secondary prevention of cardiovascular complications (CVC) was addressed in the COMPASS study. In that study, three regimens of antithrombotic therapy were compared in patients with stable atherosclerotic CVD: rivaroxaban (2.5 mg twice a day) in combination with ASA (100 mg/day); rivaroxaban (5 mg twice a day); and ASA (100 mg/day). Risk for development of major CVC (death, stroke, myocardial infarction (IM)) was lower (p<0.001) in the rivaroxaban+ASA combination treatment group than in the ASA monotherapy group; however, the risk of major bleedings was somewhat higher. Total risk based on the definition of “pure clinical benefit” was lower for the rivaroxaban+ASA combination treatment than for the ASA monotherapy. The rivaroxaban monotherapy did not result in a significant decrease in the risk of major CVC compared to the ASA monotherapy but significantly increased the risk of major bleedings. Incidence of repeated ischemic stroke for a year was 1.1% for the combination therapy, 2.6% for the rivaroxaban therapy, and 3.4% for the ASA monotherapy with significant differences between the combination treatment group and the ASA monotherapy group (p<0.01). Relative risk of repeated stroke was 67% lower for the combination therapy group compared to the ASA monotherapy group. The combination of rivaroxaban (2.5 mg twice a day) and ASA (100 mg) opens a new epoch of antithrombotic treatment for primary and secondary prevention of stroke in patients with a stable atherosclerotic CVD and sinus rhythm.

1. Kukharchuk V.V., Susekov A.V., Zubareva M.Yu., Gorniakova N.B., Aronov D.M., Akhmedzhanov N.M. et al. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations (IV revision). Cardiovascular Therapy and Prevention. 2009;8(6 S3):3–58.

2. Skvortsova V.I., Shetova I.M., Kakorina E.P., Kamkin E.G., Boyko E.L., Dashyan V.G. et al. Healthcare system for patients with stroke in Russia. Results of 10-years implementation of the measures aimed at improvement of medical care for patients with acute cerebrovascular events. Annals of clinical and experimental neurology. 2018;12(3):5– 12. DOI: 10.25692/ACEN.2018.3.1

3. Alferova V.V., Belkin A.A., Voznyuk I.A., Gerasimenko M.Yu., Geraskina L.A., Gordeev M.N. et al. Clinical guidelines for the management of patients with ischemic stroke and transient ischemic attacks. –M.: MEDpress-inform;2017. –208 p. ISBN 978-5-00030-450-1

4. Suslina Z.A., Pyradov M.A. Stroke: diagnosis, treatment, prevention. –M.: MEDpress-inform;2009. - 288 p. ISBN 5-98322-566-9

5. Tanashyan M.M., Raskurazhev A.A., Shabalina A.A., Lagoda O.V., Gnedovskaya E.V. Biomarkers of cerebral atherosclerosis: the capabilities of early diagnosis and prognosis of individual risk. Annals of clinical and experimental neurology. 2015;9(3):20–5.

6. Suslina Z.A., Tanashyan M.M., Domashenko M.A. Antithrombotic therapy of ischemic disorders of cerebral circulation. -M.: Medical Information Agency;2009. - 244 p. ISBN 978-5-89481-710-1

7. Fonyakin A.V., Geraskina L.A. Prevention of ischemic stroke. Recommendations for antithrombotic therapy. Ed. Suslina Z.A. -M.: IMAPRESS;2014. - 72 p. ISBN 978-5-904356-22-4

8. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke. 2014;45(7):2160–236. DOI: 10.1161/STR.0000000000000024

9. Tanashyan M.M. Hemostasis, hemorheology and atrombogenic activity of the vascular wall in angioneurology. Annals of clinical and experimental neurology. 2007;1(2):29–33.

10. Piradov M.A. Antiplatelet therapy in the prevention of secondary ischemic strokes. Russian Medical Journal. 2003;11(12):696–8.

11. Parfenov V.A., Verbitskaya S.V. Antiplatelet therapy in the secondary prevention of ischemic stroke. Medical Council. 2015;5:6–13.

12. Antithrombotic Tralists` Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009;373(9678):1849–60. DOI: 10.1016/S0140-6736(09)60503-1

13. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences. 1996;143(1–2):1–13. DOI: 10.1016/S0022-510X(96)00308-5

14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (London, England). 1996;348(9038):1329–39. DOI: 10.1016/s0140-6736(96)09457-3

15. Diener H-C, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebocontrolled trial. The Lancet. 2004;364(9431):331–7. DOI: 10.1016/ S0140-6736(04)16721-4

16. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine. 2006;354(16):1706–17. DOI: 10.1056/NEJMoa060989

17. The SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS et al. Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke. New England Journal of Medicine. 2012;367(9):817–25. DOI: 10.1056/NEJMoa1204133

18. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. The Lancet. 2006;367(9523):1665–73. DOI: 10.1016/S0140-6736(06)68734-5

19. Ge F, Lin H, Liu Y, Li M, Guo R, Ruan Z et al. Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. European Journal of Neurology. 2016;23(6):1051–7. DOI: 10.1111/ene.12982

20. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA. 2010;304(12):1350–7. DOI: 10.1001/jama.2010.1322

21. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. Journal of the American College of Cardiology. 2003;41(4 Suppl S):62S-69S. DOI: 10.1016/s0735-1097(02)02776-6

22. De Schryver EL, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database of Systematic Reviews. 2012;9:CD001342. DOI: 10.1002/14651858.CD001342.pub3

23. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330– 93. DOI: 10.1093/eurheartj/ehy136

24. Rychkov A.Yu., Khorkova N.Yu. Antithrombotic Therapy in Atrial Fibrillation and Chronic Ischemic Heart Disease. Kardiologiia. 2019;59(5):80–6. DOI: 10.18087/cardio.2019.5.n493

25. Turgeon RD, Ackman ML, Babadagli HE, Basaraba JE, Chen JW, Omar M et al. The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease. Journal of Cardiovascular Pharmacology and Therapeutics. 2019;24(2):103–12. DOI: 10.1177/1074248418795889

26. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. DOI: 10.1136/bmjopen-2012-001592

27. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. The New England Journal of Medicine. 2012;366(1):9–19. DOI: 10.1056/NEJMoa1112277

28. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017;377(14):1319–30. DOI: 10.1056/NEJMoa1709118

29. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018;391(10117):219–29. DOI: 10.1016/S0140-6736(17)32409-1

30. Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F et al. Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology. 2017;33(8):1027–35. DOI: 10.1016/j.cjca.2017.06.001

31. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients: Definitions of major bleeding in clinical studies. Journal of Thrombosis and Haemostasis. 2005;3(4):692–4. DOI: 10.1111/j.1538-7836.2005.01204.x

32. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V et al. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 2018;71(20):2306–15. DOI: 10.1016/j.jacc.2018.03.008

33. Anand SS, Eikelboom JW, Dyal L, Bosch J, Neumann C, Widimsky P et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology. 2019;73(25):3271–80. DOI: 10.1016/j.jacc.2019.02.079

34. Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK et al. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial. Circulation. 2019;140(7):529–37. DOI: 10.1161/CIRCULATIONAHA.119.039609

35. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139(9):1134–45. DOI: 10.1161/CIRCULATIONAHA.118.035864

36. Spronk HMH, de Jong AM, Crijns HJ, Schotten U, Van Gelder IC, ten Cate H. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovascular Research. 2014;101(3):344–51. DOI: 10.1093/cvr/cvt343

37. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials. Circulation. 2005;112(25):3855–67. DOI: 10.1161/CIRCULATIONAHA.105.573550